Effect of RO318220 on mean platelet forward scatter
. | . | Geometric mean FSC-H . | . | |
|---|---|---|---|---|
| Sample . | Condition . | Platelet mean . | Annexin V-positive mean . | |
| RO318220, μM | ||||
| 0 | Unlabeled | 97 | — | |
| 0 | Unact | 92 | — | |
| 0 | IIa 0.2 U/mL | 79 | 46 | |
| 10 | Unlabeled | 94 | — | |
| 10 | Unact | 101 | — | |
| 10 | IIa 0.2 U/mL | 78 | 52 | |
| 20 | Unlabeled | 104 | — | |
| 20 | Unact | 103 | — | |
| 20 | IIa 0.2 U/mL | 66 | 40 | |
| 100 | Unlabeled | 47 | — | |
| 100 | Unact | 41 | — | |
| 100 | IIa 0.2 U/mL | 56 | 61 | |
| Calpeptin, μM | ||||
| 0 | No | 610 | 353 | |
| 0 | Yes | 655 | 418 | |
| 100 | No | 288 | 288 | |
| 100 | Yes | 599 | 638 | |
. | . | Geometric mean FSC-H . | . | |
|---|---|---|---|---|
| Sample . | Condition . | Platelet mean . | Annexin V-positive mean . | |
| RO318220, μM | ||||
| 0 | Unlabeled | 97 | — | |
| 0 | Unact | 92 | — | |
| 0 | IIa 0.2 U/mL | 79 | 46 | |
| 10 | Unlabeled | 94 | — | |
| 10 | Unact | 101 | — | |
| 10 | IIa 0.2 U/mL | 78 | 52 | |
| 20 | Unlabeled | 104 | — | |
| 20 | Unact | 103 | — | |
| 20 | IIa 0.2 U/mL | 66 | 40 | |
| 100 | Unlabeled | 47 | — | |
| 100 | Unact | 41 | — | |
| 100 | IIa 0.2 U/mL | 56 | 61 | |
| Calpeptin, μM | ||||
| 0 | No | 610 | 353 | |
| 0 | Yes | 655 | 418 | |
| 100 | No | 288 | 288 | |
| 100 | Yes | 599 | 638 | |
Gel-filtered, aspirin-treated platelets were incubated with varying concentrations of RO318220 before activation with thrombin and exposure to FITC-labeled annexin V. Flow cytometry measured forward (FSC-H) versus side scatter (SSC-H) of unlabeled or labeled unactivated or activated platelets (defined by positive staining for FITC-anti-GP1bα).
—indicates not applicable; and Unact, unactivated.